Intratumoral PH-762 for Cutaneous Carcinoma
Running, not enrolling · Phase 1
Conditions studied: Squamous Cell Carcinoma of the Skin, Malignant Melanoma of Skin, Merkel Cell Carcinoma of Skin
In brief
The goal of this clinical trial is to evaluate the safety and tolerability of intratumoral injections of PH-762 in squamous cell carcinoma, melanoma, or Merkel cell carcinomas of the skin, to understand what the body does to the PH-762, and to observe how the tumor responds to the drug. Participants will receive four injections of PH-762 at weekly intervals, into a single tumor, followed by surgical removal of the tumor approximately two weeks later.
Key facts
- Study ID
- NCT06014086
- Run by
- Phio Pharmaceuticals Inc.
- People needed
- 30
- Starts
- 2023-11-07
- Expected to finish
- 2026-03-01
- Last updated by the study team
- 2026-02-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Banner MD Anderson Cancer Center — Gilbert, Arizona, United States
- Paradigm Clinical Research — San Diego, California, United States
- Integrity Research — Delray Beach, Florida, United States
- Skin Cancer and Dermatology Institute — Reno, Nevada, United States
- Centricity Research — Columbus, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.